PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's strategic approach to
TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies
PharmaCyte Biotech, Inc. (NASDAQ:PMCB)
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the closing of its previously announced $7 million financing.
As of April 30, 2025, PharmaCyte had approximately $15.5 million in
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or
Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women in the U.S. - -
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock,
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors
Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology,
